A patient who developed acute myocardial infarction during pegylated interferon alpha-2a and ribavirin therapy for chronic hepatitis C: A case report

Yıl 2013, Cilt: 12 Sayı: 2, 84 - 85, 01.08.2013

Nezih Pişkinpaşa - Yaşar Sertbaş - Emin Pişkinpaşa

Öz

We present the case of a 60-year-old male patient who developed acute myocardial infarction while undergoing pegylated interferon alpha-2a and ribavirin therapy for chronic C hepatitis. After two months of therapy, the patient experienced acute anterior myocardial infarction. No ischemic heart disease was diagnosed by cardiologic examinations one month before the initiation of the therapy. We believe his acute myocardial infarction was a serious side effect

Anahtar Kelimeler

Chronic hepatitis C, pegylated interferon, ribavirin, myocardial infarction

Pegile interferon alfa-2a ve ribavirin ile kronik C hepatiti tedavisi sırasında akut miyokard infarktüsü gelişen hasta: Bir olgu sunum

Öz

Kronik C hepatitinin pegile interferon alfa-2a ve ribavirin ile tedavi edilimesi sırasında akut miyokard infarktüsü gelişen 60 yaşındaki bir erkek hastayı sunuyoruz. Hasta, tedaviye başlandıktan iki ay sonra akut anterior miyokard infarktüsü geçirdi.Tedavinin bir ay öncesinde yapılan kardiyolojik tetkiklerde iskemik kalp hastalığı tespit edilememişti. Akut miyokard infarktüsünün ciddi bir yan etki olduğunu düşündük

Anahtar Kelimeler

Kronik C hepatiti, pegile interferon, ribavirin, miyokard infarktüsü

Kaynakça

• Ökten A, Demir K, Kaymakoğlu S, et al. Kronik hepatitlerin etyolojik dağılımı. Turk J Gastroenterol 1998; 2: 113-5.
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347: 975-82.
• Di Bisceglia AM, McHUtchison J, Rice CM. New therapeutic strate- gies for hepatitis C. Hepatology 2002; 35: 224-31.
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized study. Lancet 2001; 358: 958-65.
• Fried MW. Side effects of therapy of hepatitis C and their manage- ment. Hepatology 2002; 36: 237-44.
• McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl 1): 57-65.
• Kumar V, Cotran SR, Robbins SL.Temel Patoloji. In.:Çevikbaş U, ed. 6th ed. İstanbul. Nobel Tıp Kitapevi 2000; 283-9.
• Pocok SJ, Shaper G, Phillips AN. Concentrations of high density lipoprotein cholesterol, triglyserides and total cholestherol in isch- aemic heart disease. Br Med J 1989:298:998-1002.
• Graystone JT, Kuo CC, Wang SP, et al.A new chlamydia psittaci strein, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986;315:161-8.
• Teragawa H, Hondo T, Amano H, et al. Adverse effects of interfer- on on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996; 37: 905-15.
• Rechcinski T, Matusik D, Rudzinski D, et al. Exacerbation of atrio- ventricular block during treatment of hepatitis C with peginterfer- on. Polskie Archiwum Medycyny Wewnetrznej 2007; 1: 1-3.
• Hoofnagle JH, Seff LB. Peginterferon and chronic hepatitis C. N Engl J Med 2006;355:2444-51.
• Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 3: 557-61.
• Forde KA, Haynes K, Troxel AB, et al. Risk of myocardial infarction associated with chronic hepatitis C virus infection. J Viral Hepat 2012;19:271-7.